Latest news

• NICE to look again at Pfizer’s Besponsa after appeal

  NICE to look again at Pfizer’ s Besponsa after appeal. The blood cancer medicine was originally turned down on cost-effectiveness grounds. ... UK practice, however, would largely consist of using [Besponsa] as a step to enable patients to have a stem

• NICE set to reject Pfizer's leukaemia drug Besponsa

  NICE set to reject Pfizer's leukaemia drug Besponsa. Firm plans to appeal the final appraisal determination on its orphan drug. ... The National Institute of Healthcare and Excellence (NICE) is set to reject Pfizer’s orphan drug for leukaemia Besponsa

• FDA clears Pfizer's leukaemia drug Besponsa

  FDA clears Pfizer's leukaemia drug Besponsa. The breakthrough treatment is the first CD22-targeted ADC to be approved in the US. ... Besponsa has been approved with a boxed warning for hepatotoxicity and an increased risk of post-hematopoietic stem cell

• NICE rejects Pfizer's antibody drug for leukaemia

  NICE rejects Pfizer's antibody drug for leukaemia. Trial shows no survival benefit from Besponsa compared to current treatment. ... The National Institute for Health and Care Excellence (NICE) has turned down Pfizer’s leukaemia drug Besponsa in draft

• CHMP backs two rare disease therapies at April meeting

  In other news from the CHMP meeting, Pfizer picked up a positive opinion for Besponsa (inotuzumab ozogamicin) as a single-agent treatment for adults with relapsed or refractory CD22-positive